GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (OTCPK:CLTEF) » Definitions » Equity-to-Asset

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Equity-to-Asset : 0.18 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Calliditas Therapeutics AB Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Calliditas Therapeutics AB's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $32.64 Mil. Calliditas Therapeutics AB's Total Assets for the quarter that ended in Dec. 2023 was $181.26 Mil. Therefore, Calliditas Therapeutics AB's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.18.

The historical rank and industry rank for Calliditas Therapeutics AB's Equity-to-Asset or its related term are showing as below:

CLTEF' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.52   Med: 0.64   Max: 0.95
Current: 0.18

During the past 9 years, the highest Equity to Asset Ratio of Calliditas Therapeutics AB was 0.95. The lowest was -0.52. And the median was 0.64.

CLTEF's Equity-to-Asset is ranked worse than
80.32% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs CLTEF: 0.18

Calliditas Therapeutics AB Equity-to-Asset Historical Data

The historical data trend for Calliditas Therapeutics AB's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB Equity-to-Asset Chart

Calliditas Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only 0.93 0.83 0.69 0.39 0.18

Calliditas Therapeutics AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.39 0.30 0.22 0.18

Competitive Comparison of Calliditas Therapeutics AB's Equity-to-Asset

For the Biotechnology subindustry, Calliditas Therapeutics AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Calliditas Therapeutics AB's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calliditas Therapeutics AB's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Calliditas Therapeutics AB's Equity-to-Asset falls into.



Calliditas Therapeutics AB Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Calliditas Therapeutics AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=32.64/181.255
=0.18

Calliditas Therapeutics AB's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=32.64/181.255
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Calliditas Therapeutics AB  (OTCPK:CLTEF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Calliditas Therapeutics AB Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Calliditas Therapeutics AB's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description

Traded in Other Exchanges
Address
Kungsbron 1, D5, Stockholm, SWE, SE-111 22
Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.